Table 1 Characteristics of the cases and controls
Characteristics | Cases | Controls | |||
|---|---|---|---|---|---|
Low Risk N (%) | High Risk without Progression N (%) | High Risk with progression N (%) | Metastatic N (%) | Healthy N (%) | |
Number of subjects | 11 (100) | 12 (100) | 10 (100) | 9 (100) | 10 (100) |
Ethnicity | |||||
 Caucasian | 11 (100) | 12 (100) | 10 (100) | 9 (100) | 10 (100) |
| Â | Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) |
Age at blood draw (years) | 61.4 (57.6–64.6) | 62.9 (60.2–69.3) | 63.6 (60.6–68.3) | 59.8 (57–68) | 38.3 (34–40.6) |
PSA at blood draw (ng/mL) | 5.8 (4.6–6.05) | 9.32 (6.12–13.6) | 10.9 (7.65–23.9) | NAa | NAb |
Years between blood draw and event | |||||
 PSA progression (or last follow-up) | 7.59 (7.05–8.44) | 5.88 (2.99–6.96) | 0.28 (0.26–0.93) | NAa | NAb |
 local progression (or last follow-up) | 7.59 (7.05–8.44) | 6.98 (6.60–7.76) | 4.04 (1.69–6.77) | NAa | NAb |
 lymphnode progression (or last follow-up) | 7.59 (7.05–8.44) | 7.13 (6.88–7.87) | 3.16 (2.62–4.14) | NAa | NAb |
 bone progression (or last follow-up) | 7.59 (7.05–8.44) | 7.14 (6.88–7.87) | 4.42 (2.09–7.20) | NAa | NAb |
Years in follow-up | 7.59 (7.05–8.44) | 7.14 (6.88–7.87) | 5.11 (4.25–7.94) | 3.23 (1.77–4.87) | NAb |